Group 1 - Baidu Group-SW (09888) proposes to spin off Kunlun Chip for independent listing on the Hong Kong Stock Exchange main board [1] - Dali Group Holdings (01921) subsidiary Dali International Industrial Company has obtained a temporary industrial license issued by MIMR [1] - Guofu Hydrogen Energy (02582) has completed the delivery of a total of 424 sets of vehicle-mounted high-pressure hydrogen supply systems to its customers [1] Group 2 - CSPC Pharmaceutical Group (01093) has received clinical trial approval in China for its inhalation powder of Nintedanib [1] - Fantasia Holdings (01777) has entered into a restructuring agreement with Splendid Fortune to sell 409 million shares of Color Life for USD 4.5284 million [1] - China Hongqiao (01378) has made Hongtuo Industrial a wholly-owned subsidiary of Hongchuang Holdings [1] Group 3 - Brainstorm Cell Therapeutics-B (06681) subsidiary has officially signed a cooperation agreement with Beijing Jianguo Medical for a cognitive digital therapy project [1] - Longpan Technology (02465) plans to invest in a lithium iron phosphate production base with an annual capacity of 240,000 tons, with a total investment not exceeding 2 billion yuan [1] - Zhongzheng International (00943) intends to acquire a digital solution company in the beauty industry for HKD 62.5 million, with resumption of trading on January 5 [1] - Kelun-Biotech (06990) has received approval from the National Medical Products Administration for the clinical trial application of its ITGB6 ADC SKB105 new drug [1]

Investment Rating - The report indicates a positive outlook for the biopharmaceutical industry, highlighting the approval of approximately 101 innovative drugs in 2025, marking a significant growth in the sector [3]. Core Insights - The innovative drug sector in China is experiencing robust growth, with 63 domestic innovative drugs (62% of total approvals) and 38 imported innovative drugs (38% of total approvals) approved in 2025 [3]. - The report suggests several companies to watch, including those with high certainty for overseas expansion and those with potential overseas data catalysts [2][20]. - The report emphasizes the importance of upcoming catalysts such as academic conferences and data releases that could impact the sector positively [2]. Summary by Sections Weekly New Drug Market Review - From December 29, 2025, to January 4, 2026, the top five gainers in the new drug sector were Youzhiyou (+12.45%), Aidi Pharmaceutical (+8.07%), Yongtai Biological (+6.72%), Kaituo Pharmaceutical (+6.25%), and Yahong Pharmaceutical (+4.07%). The top five losers were Jakes (+-15.53%), Yunding Xinyao (-15.06%), Kedi (-11.73%), Gelei Pharmaceutical (-8.64%), and Kangning Jere (-8.06%) [1][16]. Weekly Focused Stocks - The report recommends focusing on companies with MNC certification and high certainty for overseas volume, such as Sanofi Pharmaceutical, Lianbang Pharmaceutical, and Kelun Biotech. It also highlights companies with potential overseas data catalysts like Betta Pharmaceuticals and Hengrui Medicine [2][20]. Weekly New Drug Industry Analysis - The report notes that 2025 saw a record high in the number of approved innovative drugs in China, with a total of approximately 101 drugs approved by NMPA, excluding new indications, modified new drugs, biosimilars, traditional Chinese medicine, and vaccines [3][21]. Weekly New Drug Application Approval & Acceptance - No new drug or new indication applications were approved this week, but four new drug or new indication applications were accepted [4][27]. Weekly New Drug Clinical Application Approval & Acceptance - This week, 18 new drug clinical applications were approved, and 52 new drug clinical applications were accepted [5][30].

Investment Rating - The report indicates a positive investment outlook for the innovative pharmaceutical and supply chain industry in China, highlighting a shift towards companies with core technological platforms and clear clinical value [5][9]. Core Insights - The year 2025 is identified as a pivotal moment for China's innovative pharmaceutical industry, characterized by a trend of "differentiation" where capital is increasingly directed towards companies with substantial technological capabilities and global potential [5][6]. - The policy environment has transitioned from merely encouraging innovation to providing systematic and precise guidance throughout the entire drug development lifecycle, enhancing the industry's overall efficiency and quality [9][20]. - The report emphasizes the importance of identifying true value in the industry amidst a backdrop of significant changes, with a focus on product strength, platform capabilities, and global operational abilities [6][11]. Summary by Sections 1. Industry Policy and Capital Market Trends - The Chinese innovative pharmaceutical policy system has entered a new phase of systematic guidance, covering all stages from research and clinical trials to market access and payment [17][25]. - Over 300 national and local policies have been issued in 2025, with a focus on enhancing clinical value and high-quality development [18][20]. - Capital is increasingly concentrated on late-stage projects and cutting-edge technologies, with a notable increase in BD transactions and a shift towards more complex collaboration models [9][26][28]. 2. Product and Technology Innovations - Significant breakthroughs in clinical and commercial value are expected in 2025, particularly in areas such as ADCs, bispecific antibodies, and cell therapies [10][11]. - The report highlights the emergence of new opportunities driven by existing pain points, particularly in CAR-T therapies and the development of universal CAR-T solutions [12][14]. - The report also notes the rapid iteration of technologies and the differentiation of product offerings, with a focus on platform-based approaches gaining international recognition [12][14]. 3. Future Trends and Predictions - The report predicts a shift in technological paradigms, with a focus on clinical and commercial value realization in innovative therapies [13][16]. - The competitive landscape is expected to evolve from single-point breakthroughs to a more integrated global capability competition [13][16]. - Changes in payment systems are anticipated, with a move towards making innovative drugs essential rather than optional in healthcare [13][16].

Investment Rating - The report maintains a "Recommended" rating for several companies in the healthcare sector, including Weili Medical, Zhend Medical, Aohua Endoscopy, and others [33]. Core Insights - The report highlights a shift in the innovative drug sector from quantity to quality, emphasizing the importance of differentiated products and internationalization for future profitability [11]. - The medical device sector is experiencing a recovery in bidding volumes, particularly in imaging equipment, and is expected to benefit from government subsidies for home medical devices [11][19]. - The life sciences service sector is showing signs of recovery, with increasing demand driven by both domestic and international markets [23]. - The pharmacy sector is poised for growth due to the acceleration of prescription outflow and an improving competitive landscape [24]. Summary by Sections Market Review - The report notes a 2.02% decline in the CITIC Medical Index, underperforming the CSI 300 Index by 1.44 percentage points, ranking 27th among 30 sectors [7]. Innovative Drugs - The innovative drug sector is expected to see a significant increase in the number of products launched, with projections of over 30 products by 2027, and a revenue share from innovative products expected to exceed 50% by 2025 [15]. Medical Devices - The report identifies a recovery in bidding for imaging devices and highlights the potential for domestic companies to increase market share through product upgrades and international expansion [19][20]. Life Sciences Services - The life sciences service sector is anticipated to benefit from a recovery in overseas demand and an increase in domestic industrial demand, with a focus on mergers and acquisitions to strengthen market positions [23]. Pharmacies - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with recommendations to focus on leading pharmacy chains [24]. Traditional Chinese Medicine - The report emphasizes the importance of basic medicines and state-owned enterprise reforms, suggesting a focus on companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical [27]. Medical Services - The report recommends focusing on companies with national expansion capabilities in the medical services sector, particularly those in traditional Chinese medicine and ophthalmology [26]. Blood Products - The blood products sector is expected to see growth due to relaxed approval processes for plasma stations and an increase in product offerings [12].

Market Overview - The CITIC Pharmaceutical Index decreased by 2.02%, underperforming the CSI 300 Index by 1.44 percentage points, ranking 27th among 30 primary industries [8] - The top ten stocks with the highest gains this week include Duorui Pharmaceutical, Maillande, and Xiangyu Medical, while the top ten stocks with the largest declines include *ST Changyao and Shuyupingmin [8][37] Overall View and Investment Themes - The domestic innovative drug industry is transitioning from quantity logic to quality logic, emphasizing differentiated and internationalized pipelines, with a focus on products that can generate profits [11] - In the medical device sector, there is a notable recovery in bidding volumes for imaging equipment, and the home medical device market is benefiting from subsidy policies [11] - The CXO and life sciences services sector is expected to see a rebound in overseas investment and a bottoming out of domestic investment, indicating a potential upturn in the innovation chain [11] - The specialty raw materials pharmaceutical industry is anticipated to experience a new growth cycle, with a focus on the impact of patent expirations on new product volumes [11] Specific Industry Insights Innovative Drugs - The company has significantly increased its pipeline, with the number of innovative products rising from 3 to 18 since 2022, and plans to launch an average of 5 innovative products annually over the next three years [15][16] - The revenue share from innovative products is expected to exceed 50% by 2025, driven by a robust pipeline and strategic partnerships [15][16] Medical Devices - The orthopedic market is projected to grow due to aging demographics and increased surgery penetration, with domestic companies benefiting from the acceleration of local replacements [17] - The IVD market, particularly in chemiluminescence, is expected to grow rapidly, with domestic brands increasing their market share through competitive pricing and improved product offerings [18] Life Sciences Services - The life sciences services sector is recovering, with demand expected to rise in both domestic and overseas markets, driven by increased investment in biopharmaceuticals [24] - The industry is characterized by low penetration rates and a trend towards domestic substitution, with significant opportunities for growth through mergers and acquisitions [24] Traditional Chinese Medicine and Medical Services - The traditional Chinese medicine sector is expected to benefit from policy changes and an aging population, with a focus on unique therapeutic areas and high-dividend stocks [26][31] - The medical services sector is anticipated to improve due to anti-corruption measures and the expansion of commercial insurance, enhancing the competitiveness of private healthcare providers [26] Investment Recommendations - The company recommends focusing on the pharmacy sector due to the acceleration of prescription outflow and the optimization of competitive dynamics, suggesting that the pharmacy sector is poised for recovery [25] - In the medical device sector, attention is drawn to companies that are well-positioned to benefit from domestic substitution and technological advancements [19]

Core Viewpoint - The approval of the inhaled powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant milestone for the company, as it is the first inhalation formulation approved for clinical trials in China for the treatment of pulmonary fibrosis [1][1]. Group 1 - The inhaled formulation of Nintedanib has received approval for clinical trials in China [1]. - This product is the first of its kind in China specifically aimed at treating pulmonary fibrosis [1][1].

Group 1: Company Performance and Market Position - 和誉-B has a total market value of 88 million HKD and a recent price of 12.90 HKD, with a year-to-date increase of 199.3% since its inclusion on November 1, 2024[3] - 宜明昂科-B has a market value of 27 million HKD, with a recent price of 6.17 HKD, showing a decline of 10.7% since its inclusion on April 2, 2025[3] - 石药集团 has a market value of 987 million HKD, with a recent price of 8.57 HKD, and is expected to recover quickly post-2025 as key innovative drugs are launched[3] Group 2: Financial Metrics and Projections - 和誉-B's EPS for 2024 is projected at 0.04 HKD, with a PE ratio of 298.65 and a PB ratio of 86.00[3] - 宜明昂科-B's EPS for 2025E is projected at -0.91 HKD, with a PE ratio of -10.28 and a PB ratio of 3.63[3] - 石药集团's EPS for 2024 is projected at 0.40 HKD, with a PE ratio of 21.52 and a PB ratio of 2.83[3] Group 3: Strategic Developments - 和誉-B has signed a licensing agreement with Merck for exclusive commercialization rights in Greater China, with a total agreement value of 605.5 million USD, including a 70 million USD upfront payment[3] - 猎豹移动's AI business revenue has increased by approximately 100% year-on-year, indicating strong market demand and commercialization capabilities[3] - 阿里巴巴 is focusing on high CAPEX investments in AI and cloud services, with a market value of 27,354 million HKD and a recent price of 143.30 HKD, expected to enhance revenue growth[3]

Core Insights - The key opportunity for local biotech companies lies in focusing on original innovation from 0 to 1, establishing core technological barriers in unmet clinical needs, and achieving a leap from follower to leader [2][14] - Chinese innovative pharmaceutical companies have entered the global ADC innovation core camp, with over 50% of the global ADC new drug pipeline originating from China [1][14] - The strategic partnership between BaiLi TianHeng and BMS in the ADC field has set a record for the highest single-asset transaction in the global ADC sector, further elevating industry innovation [1][5] Industry Trends - The BD (business development) boom in the ADC sector is expected to continue into 2025, with 14 transactions in the first eight months of 2023, making ADC one of the hottest outbound technology tracks [1][14] - Companies are expanding beyond mature targets like HER2 and TROP2 to explore "blue ocean" targets such as CDH6, CDH17, and DLL3, seeking broader treatment windows and improved competitive landscapes [1][14] Strategic Partnerships - The partnership model of "self-researched core assets + global rights cooperation" and "co-development + co-commercialization" is relatively rare globally, requiring high product strength and a forward-looking strategic vision [7][9] - BaiLi TianHeng's collaboration with BMS is notable for its potential total transaction value of up to $8.4 billion, highlighting the growing trend of significant transactions in the oncology treatment sector [5][9] Challenges and Opportunities - Despite the increasing number of transactions, many Chinese innovative drug assets remain undervalued due to a lack of global clinical trial validation and lower payment prices in the domestic market [9][12] - The development of "super blockbuster" products with strong product power is seen as a key path to overcoming valuation challenges, with the drug iza-bren being recognized as a first-in-class product [9][12] Future Directions - The competition in the "ADC + IO" (immuno-oncology) space is intensifying, with both multinational and domestic companies actively pursuing innovative combinations [10][14] - To achieve comprehensive internationalization, Chinese pharmaceutical companies must overcome four core capability gaps: global leading R&D capabilities, global clinical development capabilities, global supply chain capabilities, and global commercialization capabilities [12][13]

Core Viewpoint - The approval of the inhalation powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant advancement for the treatment of idiopathic pulmonary fibrosis (IPF) in the country, being the first inhalation formulation approved for clinical trials in China [1] Group 1 - The inhalation powder formulation of Nintedanib has received approval for clinical trials in China [1] - Nintedanib is a multi-tyrosine kinase inhibitor that can slow the progression of idiopathic pulmonary fibrosis (IPF) [1] - The currently available formulation of Nintedanib is an oral soft capsule [1]

Core Viewpoint - The approval of the inhaled powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant advancement in the treatment of pulmonary fibrosis, being the first inhaled formulation approved for clinical trials in China [1] Group 1: Product Development - The inhaled formulation of Nintedanib is a multi-tyrosine kinase inhibitor that can slow the progression of idiopathic pulmonary fibrosis (IPF) [1] - The product offers significant advantages over oral formulations, including improved lung exposure, better lung function, reduced systemic exposure, and significantly lower gastrointestinal side effects [1] - Preclinical studies indicate that the product can achieve equivalent efficacy at a dosage of 1/200 of the oral dose, demonstrating good safety and effectiveness [1] Group 2: Clinical Applications - The approved clinical indication for the product is idiopathic pulmonary fibrosis, with potential applications for treating systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive pulmonary fibrosis (PPF) [1] - This approval is a key achievement for the company's inhalation technology platform, laying a solid foundation for the development of subsequent inhaled formulations in the pipeline [1]